General Information
Version
1.0.0
Revision date
2017-07-10
Product name
Palonosetron Hydrochloride/ Fosnetupitant phosphate DP
Product name
Palonosetron Hydrochloride/ Fosnetupitant phosphate DP
Identification on the label/Trade name
None identified
Product Synonyms
None identified
Chemical name
Mixture - contains an isoquinoline derivative (palonestron HCl) and a butyramide
1.2.1 Relevant identified uses
Bulk formulated pharmaceutical mixture/ Formulated pharmaceutical product in of the substance or vials; used to treat nausea mixture and uses
Icons in SDS
Company Information
company name
Helsinn Birex Pharmaceuticals, ltd
e-mail address of the competent person responsible for the Safety Data Sheet
sds-query@helsinn.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H361d
Hazard statements
Code
Statements
H361d
Suspected of damaging the unborn child.
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
substance or mixture Globally Harmonized Reproductive Toxicity - Category 2. System [GHS] Other/Supplemental Mixture not yet fully tested
2.2 Label elements
SECTION 2 - HAZARDS IDENTIFICATION …continued
Signal word
Warning
Hazard statements
H361d - Suspected of damaging the unborn child. precautions have been read and understood. P280 - Wear protective gloves/eye protection/face protection. P308 + P313 - IF exposed or concerned: get medical advice/attention. P405 - Store locked up. P501 - Dispose of contents/container to location in accordance with local/regional/national/international regulations.
Precautionary statements
P201 - Obtain special instructions before use. P202 - Do not handle until all safety
2.3 Other hazards
Contains active pharmaceutical ingredients that block specific neurotransmitters involved in feelings of nausea, indicated for the treatment of post-chemotherapy nausea and vomiting. Palonosetron hydrochloride (HCl) blocks a specific serotonin receptor and fosnetupitant phosphate is a prodrug that is metabolized to its active form netupitant, an NK1 receptor blocker. Adverse effects were not identified, but are expected be similar to palonosetron hydrochloride/netupitant and may include: headache, constipation, diarrhea, dizziness, transient changes in heart rate, weakness, hyperkalemia (increased blood potassium levels), and anxiety. In clinical trials, IV doses of fosnetupitant 260 mg/ palonosetron HCl 0.25 mg were investigated. Prolongation of the QT interval (a component of the heart's electrical cycle) may also occur with use based on effects observed in non-clinical studies with netupitant and palonosetron at very high doses; this is a known class effect of similar serotonin receptor antagonists. Based on the mechanism of action and effects observed in non-clinical studies in rabbits with netupitant, a potential for palonosetron/fosnetupitant to cause developmental toxicity cannot be excluded in the absence of data. Note This mixture/product is classified as hazardous under GHS as implemented by